Inhibition of Phosphodiesterase Type 3 Dilates the Rat Ductus Arteriosus Without Inducing Intimal Thickening

Circulation Journal

Volumn 76, Issue 10, 2012, Pages 2456-2464

  Ichikawa, Yasuhiro ^a   Yokoyama, Utako ^a   Iwamoto, Mari ^a   Oshikawa, Jin ^a   Okumura, Satoshi ^a   Sato, Motohiko ^a   Yokota, Shumpei ^a   Masuda, Munetaka ^a   Asou, Toshihide ^b   Ishikawa, Yoshihiro ^a  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

^b KANAGAWA CHILDREN'S MEDICAL CENTER   (Japan)

Author keywords

Congenital heart disease; Ductus arteriosus; Milrinone; Phosphodiesterase

Indexed keywords

CYCLIC AMP; HYALURONIC ACID; LOPRINONE; MILRINONE; PHOSPHODIESTERASE III; PROSTAGLANDIN E1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTERY DIAMETER; ARTERY INTIMA PROLIFERATION; ARTICLE; BREATHING RATE; CELL MIGRATION; CELL PROLIFERATION; CLINICAL ARTICLE; CONGENITAL HEART DISEASE; CONTROLLED STUDY; DUCTUS ARTERIOSUS; ENZYME INHIBITION; FETUS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFANT; NEWBORN; NONHUMAN; PROTEIN EXPRESSION; RADIOIMMUNOASSAY; RAT; RESPIRATORY DISTRESS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VASODILATATION;

ALPROSTADIL; ANIMALS; ANIMALS, NEWBORN; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 3; DUCTUS ARTERIOSUS; DUCTUS ARTERIOSUS, PATENT; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; INFANT, NEWBORN; MALE; MUSCLE, SMOOTH, VASCULAR; PHOSPHODIESTERASE 3 INHIBITORS; RATS, WISTAR; RNA, MESSENGER; VASODILATION;

EID: 84867866693     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-12-0215     Document Type: Article

References (36)

1. Yokoyama U, Minamisawa S, Quan H, Ghatak S, Akaike T, Segi-Nishida E, et al. Chronic activation of the prostaglandin receptor EP4 promotes hyaluronan-mediated neointimal formation in the ductus arteriosus. J Clin Invest 2006; 116: 3026-3034.
2. Yokoyama U, Minamisawa S, Katayama A, Tang T, Suzuki S, Iwatsubo K, et al. Differential regulation of vascular tone and remodeling via stimulation of type 2 and type 6 adenylyl cyclases in the ductus arteriosus. Circ Res 2010; 106: 1882-1892.
3. Smith GC. The pharmacology of the ductus arteriosus. Pharmacol Rev 1998; 50: 35-58.
4. Yokoyama U, Minamisawa S, Ishikawa Y. Regulation of vascular tone and remodeling of the ductus arteriosus. J Smooth Muscle Res 2010; 46: 77-87.
5. Sussmann M, Sarbia M, Meyer-Kirchrath J, Nusing RM, Schror K, Fischer JW. Induction of hyaluronic acid synthase 2 (HAS2) in human vascular smooth muscle cells by vasodilatory prostaglandins. Circ Res 2004; 94: 592-600.
6. Mitani Y, Takabayashi S, Sawada H, Ohashi H, Hayakawa H, Ikeyama Y, et al. Fate of the "opened" arterial duct: Lessons learned from bilateral pulmonary artery banding for hypoplastic left heart syndrome under the continuous infusion of prostaglandin E1. J Thorac Cardiovasc Surg 2007; 133: 1653-1654.
7. Maurice DH, Palmer D, Tilley DG, Dunkerley HA, Netherton SJ, Raymond DR, et al. Cyclic nucleotide phosphodiesterase activity, expression, and targeting in cells of the cardiovascular system. Mol Pharmacol 2003; 64: 533-546.
8. Begum N, Hockman S, Manganiello VC. Phosphodiesterase 3A (PDE3A) deletion suppresses proliferation of cultured murine vascular smooth muscle cells (VSMCs) via inhibition of mitogen-activated protein kinase (MAPK) signaling and alterations in critical cell cycle regulatory proteins. J Biol Chem 2011; 286: 26238-26249.
9. Klein L, O'Connor CM, Leimberger JD, Gattis-Stough W, Pina IL, Felker GM, et al. Lower serum sodium is associated with increased short-term mortality in hospitalized patients with worsening heart failure: Results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) study. Circulation 2005; 111: 2454-2460.
10. Niemann JT, Garner D, Khaleeli E, Lewis RJ. Milrinone facilitates resuscitation from cardiac arrest and attenuates postresuscitation myocardial dysfunction. Circulation 2003; 108: 3031-3035.
11. Greenberg B. Acute decompensated heart failure: Treatments and challenges. Circ J 2012; 76: 532-543.
12. Thomas SS, Nohria A. Hemodynamic classifications of acute heart failure and their clinical application: An update. Circ J 2012; 76: 278-286.
13. Bassler D, Choong K, McNamara P, Kirpalani H. Neonatal persistent pulmonary hypertension treated with milrinone: Four case reports. Biol Neonate 2006; 89: 1-5.
14. Bassler D, Kreutzer K, McNamara P, Kirpalani H. Milrinone for persistent pulmonary hypertension of the newborn. Cochrane Database Syst Rev 2010; (11): CD007802.
15. Toyoshima K, Momma K, Imamura S, Nakanishi T. In vivo dilatation of the fetal and postnatal ductus arteriosus by inhibition of phosphodiesterase 3 in rats. Biol Neonate 2006; 89: 251-256.
16. Liu H, Manganiello V, Waleh N, Clyman RI. Expression, activity, and function of phosphodiesterases in the mature and immature ductus arteriosus. Pediatr Res 2008; 64: 477-481.
17. Yokoyama U, Minamisawa S, Adachi-Akahane S, Akaike T, Naguro I, Funakoshi K, et al. Multiple transcripts of Ca2+ channel alpha1-subunits and a novel spliced variant of the alpha1C-subunit in rat ductus arteriosus. Am J Physiol Heart Circ Physiol 2006; 290: H1660-H1670.
18. Akaike T, Jin MH, Yokoyama U, Izumi-Nakaseko H, Jiao Q, Iwasaki S, et al. T-type Ca2+ channels promote oxygenation-induced closure of the rat ductus arteriosus not only by vasoconstriction but also by neointima formation. J Biol Chem 2009; 284: 24025-24034.
19. Yokoyama U, Patel HH, Lai NC, Aroonsakool N, Roth DM, Insel PA. The cyclic AMP effector Epac integrates pro- and anti-fibrotic signals. Proc Natl Acad Sci USA 2008; 105: 6386-6391.
20. Hoffman TM, Wernovsky G, Atz AM, Kulik TJ, Nelson DP, Chang AC, et al. Efficacy and safety of milrinone in preventing low cardiac output syndrome in infants and children after corrective surgery for congenital heart disease. Circulation 2003; 107: 996-1002.
21. Taoka M, Shiono M, Hata M, Sezai A, Iida M, Yoshitake I, et al. Child with fulminant myocarditis survived by ECMO Support: Report of a child case. Ann Thorac Cardiovasc Surg 2007; 13: 60-64.
22. Lewis AB, Freed MD, Heymann MA, Roehl SL, Kensey RC. Side effects of therapy with prostaglandin E1 in infants with critical congenital heart disease. Circulation 1981; 64: 893-898.
23. Tananari Y, Maeno Y, Takagishi T, Sasaguri Y, Morimatsu M, Kato H. Role of apoptosis in the closure of neonatal ductus arteriosus. Jpn Circ J 2000; 64: 684-688.
24. Boudreau N, Rabinovitch M. Developmentally regulated changes in extracellular matrix in endothelial and smooth muscle cells in the ductus arteriosus may be related to intimal proliferation. Lab Invest 1991; 64: 187-199.
25. Reinhardt RR, Chin E, Zhou J, Taira M, Murata T, Manganiello VC, et al. Distinctive anatomical patterns of gene expression for cGMPinhibited cyclic nucleotide phosphodiesterases. J Clin Invest 1995; 95: 1528-1538.
26. Palmer D, Maurice DH. Dual expression and differential regulation of phosphodiesterase 3A and phosphodiesterase 3B in human vascular smooth muscle: Implications for phosphodiesterase 3 inhibition in human cardiovascular tissues. Mol Pharmacol 2000; 58: 247-252.
27. Breyer RM, Bagdassarian CK, Myers SA, Breyer MD. Prostanoid receptors: Subtypes and signaling. Annu Rev Pharmacol Toxicol 2001; 41: 661-690.
28. Houslay MD. Underpinning compartmentalised cAMP signaling through targeted cAMP breakdown. Trends Biochem Sci 2010; 35: 91-100.
29. Netherton SJ, Jimmo SL, Palmer D, Tilley DG, Dunkerley HA, Raymond DR, et al. Altered phosphodiesterase 3-mediated cAMP hydrolysis contributes to a hypermotile phenotype in obese JCR: LA-cp rat aortic vascular smooth muscle cells: Implications for diabetes-associated cardiovascular disease. Diabetes 2002; 51: 1194-1200.
30. Souness JE, Hassall GA, Parrott DP. Inhibition of pig aortic smooth muscle cell DNA synthesis by selective type III and type IV cyclic AMP phosphodiesterase inhibitors. Biochem Pharmacol 1992; 44: 857-866.
31. Pullamsetti S, Krick S, Yilmaz H, Ghofrani HA, Schudt C, Weissmann N, et al. Inhaled tolafentrine reverses pulmonary vascular remodeling via inhibition of smooth muscle cell migration. Respir Res 2005; 6: 128.
32. Meckler GD, Lowe C. To intubate or not to intubate? Transporting infants on prostaglandin E1. Pediatrics 2009; 123: e25-e30.
33. Shin DD, Brandimarte F, de Luca L, Sabbah HN, Fonarow GC, Filippatos G, et al. Review of current and investigational pharmacologic agents for acute heart failure syndromes. Am J Cardiol 2007; 99: 4A-23A.
34. Smith AH, Owen J, Borgman KY, Fish FA, Kannankeril PJ. Relation of milrinone after surgery for congenital heart disease to significant postoperative tachyarrhythmias. Am J Cardiol 2011; 108: 1620-1624.
35. Yasuda K, Koyama N, Nomura T, Suzuki Y. Effects of phosphodiesterase 3 inhibitors to premature PDA. J Jpn Soc Prem Newborn Med 2004; 16: 395(in Japanese).
36. Nakamura M, Yamanouchi T, Taguchi T, Suita S. Effect of phosphodiesterase III inhibitor on persistent pulmonary hypertension of neonate associated with congenital diaphragmatic hernia: A case report. J Jpn Soc Pediatr Surg 2001; 37: 1073-1077(in Japanese).